Clinical Trial Update: Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Bevacizumab combined with CHOP and Rituximab as first-line therapy for untreated mantle cell lymphoma; results were posted after comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Untreated Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-10-20